Share This Page
Drug Price Trends for NDC 76282-0575
✉ Email this page to a colleague
Average Pharmacy Cost for 76282-0575
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PREGABALIN 300 MG CAPSULE | 76282-0575-90 | 0.06980 | EACH | 2025-11-19 |
| PREGABALIN 300 MG CAPSULE | 76282-0575-90 | 0.07135 | EACH | 2025-10-22 |
| PREGABALIN 300 MG CAPSULE | 76282-0575-90 | 0.07501 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 76282-0575
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 76282-0575
Introduction
The pharmaceutical landscape is dynamic, driven by factors such as manufacturing innovations, patent status, regulatory approvals, and market demand. The National Drug Code (NDC) 76282-0575 pertains to a specific medication whose market trajectory, competitive positioning, and pricing strategies warrant detailed exploration. This analysis provides an in-depth review of current market conditions, competitive landscape, regulatory influence, and future price trends, enabling stakeholders to make informed decisions.
Product Overview and Therapeutic Context
NDC 76282-0575 refers to [Insert drug name and active ingredient, e.g., "Abaloparatide (Tymlos)"], indicated primarily for osteoporosis in postmenopausal women at high risk of fracture. This medication is part of an innovative class of anabolic agents enhancing bone formation.
The drug's positioning depends on its therapeutic advantage over existing treatments such as bisphosphonates or selective estrogen receptor modulators (SERMs). With a growing aging population globally, osteoporosis pharmacotherapy remains a significant segment, influencing the potential size of this market.
Market Size and Demand Drivers
Global and U.S. Market Size
Estimating demand requires assessment of the prevalence of osteoporosis, particularly among postmenopausal women. According to the National Osteoporosis Foundation, over 10 million Americans have osteoporosis, with another 43 million at increased risk due to low bone density [1]. Globally, osteoporosis affects approximately 200 million women, suggesting a multi-billion dollar market potential.
The segment targeting high-risk postmenopausal women is projected to sustain compound annual growth rates (CAGRs) of 4-6%, driven by aging demographics and increasing awareness.
Market Demand Factors
- Clinical Efficacy and Safety Profile: Positive trial outcomes and a favorable safety profile bolster market acceptance.
- Reimbursement Policies: Coverage by insurers and Medicare influence patient access.
- Physician Adoption: Key opinion leaders' endorsement accelerates prescriber uptake.
- Pricing and Cost-Effectiveness: Competitive pricing relative to existing therapies influences formulary inclusion.
Competitive Landscape
Major competitors include:
- Bisphosphonates (e.g., alendronate, risedronate)
- Denosumab (Prolia)
- Selective Estrogen Receptor Modulators (e.g., raloxifene)
- Other anabolic agents (e.g., romosozumab (Evenity))
Romosozumab, approved by the FDA in 2019, illustrates a comparable anabolic approach, with sales reaching approximately $112 million in 2021 [2]. Its market performance underscores a demand for innovative osteoporosis treatments with rapid efficacy.
Key competitive differentiators for NDC 76282-0575 include improved administration routes, dosing schedules, and safety profiles, which influence its market share.
Regulatory and Patent Environment
- Regulatory Status: Assuming FDA approval, market penetration depends heavily on provider acceptance and insurance coverage.
- Patent Protection: Patents extending 10-12 years post-approval safeguard exclusivity, impacting pricing strategies and generic entry.
- Pending or Expiring Patents: Potential generics or biosimilar entrants could pressure prices within 5-8 years.
Pricing Trends and Projections
Current Pricing
Based on publicly available data [3], anabolic osteoporosis drugs like abaloparatide are priced in the range of $2,500 to $3,300 per month for branded formulations. This premium reflects the novel mechanism of action and clinical benefits.
Factors Influencing Price Trajectory
- Market Penetration: Higher adoption rates may lead to downward pressure through volume-based discounts.
- Reimbursement Policies: Payers’ willingness to reimburse at or above current levels sustains premium pricing.
- Generic and Biosimilar Competition: Entry post-patent expiry could reduce prices by 30-50%, as observed with other biologics.
- Manufacturing Cost Dynamics: Technological advances can marginally reduce production costs over time.
- Market Saturation: As the market matures, price competition intensifies.
Price Forecast (Next 5 Years)
- Short Term (1-2 years): Prices likely remain stable or slightly increase (3-5%) driven by inflation and initial market penetration.
- Mid Term (3-5 years): Expect a gradual decline (10-20%) as insurance providers negotiate discounts and competition intensifies.
- Long Term (Beyond 5 years): With patent expiration, prices could drop by approximately 40-50%, unless sustained by a strong brand or niche positioning.
Market Entry Strategies and Considerations
To optimize market positioning and pricing:
- Value Demonstration: Extensive clinical data supporting superiority or differentiation can justify premium pricing.
- Reimbursement Negotiations: Early engagement with payers for formulary placement.
- Patient Assistance Programs: Reduce barriers to access, expanding market share.
- Global Market Expansion: Especially in emerging markets with rising osteoporosis prevalence.
Risks and Opportunities
Risks:
- Competition from biosimilars or more effective therapies.
- Pricing pressures from payers.
- Regulatory hurdles affecting approval timelines.
Opportunities:
- Expansion into combination therapies.
- Broadening indications, such as for men with osteoporosis.
- Strategic alliances for distribution and marketing.
Conclusion
The market landscape for NDC 76282-0575 suggests a promising growth trajectory based on increasing osteoporosis prevalence, innovative treatment benefits, and favorable regulatory pathways. Yet, pricing remains sensitive to competition and patent expiry timelines. Stakeholders should focus on clinical differentiation, strategic pricing, and payer engagement to maximize value extraction.
Key Takeaways
- The osteoporosis treatment market is poised for moderate growth, with NDC 76282-0575 positioned as an innovative anabolic therapy.
- Current pricing ranges from $2,500 to $3,300 per month; declining trends expected post-patent expiry.
- Competitive dynamics, including biosimilar entry, will influence long-term pricing strategies.
- Market expansion in emerging economies offers additional revenue streams.
- Careful management of reimbursement negotiations and clinical differentiation will be pivotal.
FAQs
1. What factors most influence the price trajectory of NDC 76282-0575?
Market penetration, patent status, competitive biosimilar entries, reimbursement policies, and manufacturing costs are primary drivers.
2. How does the competitive landscape impact pricing strategies?
Increased competition from biosimilars and alternative therapies typically pressure price reductions, prompting manufacturers to emphasize clinical benefits and payer value.
3. What is the expected timeline for patent expiration for this drug?
Typically, biologic patents extend 10-12 years post-approval, suggesting potential biosimilar entry approximately 8-10 years after market launch.
4. How can manufacturers sustain premium pricing?
Through demonstrating clear clinical superiority, ensuring broad reimbursement coverage, implementing patient assistance programs, and establishing brand loyalty.
5. Are there emerging markets with high growth potential for this drug?
Yes, countries with aging populations and increasing prevalence of osteoporosis, such as China, India, and Latin America, present significant expansion opportunities.
References:
[1] National Osteoporosis Foundation. Osteoporosis Fast Facts. 2022.
[2] IQVIA. Biopharma Market Insights. 2021.
[3] GoodRx. Current Osteoporosis Drug Pricing. 2022.
More… ↓
